Discovery of a small-molecule NDR1 agonist for prostate cancer therapy

Discovery of a small-molecule NDR1 agonist for prostate cancer therapy

Prostatic cancer (PCa) is a common malignant neoplasm in men worldwide. Most patients develop castration-resistant prostate cancer (CRPC) after treatment with androgen deprivation therapy (ADT), usually resulting in death. Therefore, investigating new therapeutic targets and drugs for PCa patients i...

Full description

Bibliographic Details
Main Authors: Yang Bai, Xiuyuan Sui, Zuodong Xuan, Yifan Du, Meiling Fu, Zeyuan Zheng, Kunao Yang, Chunlan Xu, Yankuo Liu, Bin Liu, Min Zhong, Zhengying Zhang, Jianzhong Zheng, Xiaoyan Hu, Lei Zhang, Huimin Sun, Chen Shao
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Pharmacology
Subjects:
NDR1
castration-resistant prostate cancer
small-molecule compound
cancer therapy
target
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1367358/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1367358/full

Similar Items